JP2016525600A - シクロデキストリン - Google Patents
シクロデキストリン Download PDFInfo
- Publication number
- JP2016525600A JP2016525600A JP2016526700A JP2016526700A JP2016525600A JP 2016525600 A JP2016525600 A JP 2016525600A JP 2016526700 A JP2016526700 A JP 2016526700A JP 2016526700 A JP2016526700 A JP 2016526700A JP 2016525600 A JP2016525600 A JP 2016525600A
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- sbe
- substitution
- reaction
- ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361847509P | 2013-07-17 | 2013-07-17 | |
| GB1312737.8 | 2013-07-17 | ||
| US61/847,509 | 2013-07-17 | ||
| GBGB1312737.8A GB201312737D0 (en) | 2013-07-17 | 2013-07-17 | Cyclodextrin |
| PCT/GB2014/052173 WO2015008066A1 (en) | 2013-07-17 | 2014-07-16 | Cyclodextrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525600A true JP2016525600A (ja) | 2016-08-25 |
| JP2016525600A5 JP2016525600A5 (enExample) | 2016-10-06 |
Family
ID=49081370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526700A Pending JP2016525600A (ja) | 2013-07-17 | 2014-07-16 | シクロデキストリン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11117978B2 (enExample) |
| EP (1) | EP3022231B1 (enExample) |
| JP (1) | JP2016525600A (enExample) |
| KR (1) | KR20160031019A (enExample) |
| CN (1) | CN105431458A (enExample) |
| AP (1) | AP2016008975A0 (enExample) |
| AU (1) | AU2014291800A1 (enExample) |
| CA (1) | CA2919501A1 (enExample) |
| CL (1) | CL2016000082A1 (enExample) |
| GB (3) | GB201312737D0 (enExample) |
| HU (1) | HUE038911T2 (enExample) |
| MX (1) | MX2016000553A (enExample) |
| PT (1) | PT3022231T (enExample) |
| WO (1) | WO2015008066A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| US11118217B2 (en) | 2017-01-30 | 2021-09-14 | Bio-Rad Laboratories, Inc. | Emulsion compositions and methods of their use |
| US11274164B2 (en) | 2017-02-07 | 2022-03-15 | Biophore India Pharmaceuticals Pvt. Ltd. | Method for the preparation of sulfobutylether beta cyclodextrin sodium |
| CN112557541B (zh) * | 2020-12-08 | 2022-07-12 | 河北科技大学 | 一种枸橼酸马罗匹坦及其有关物质的检测方法 |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
| CN114369177A (zh) * | 2021-12-31 | 2022-04-19 | 贵州省欣紫鸿药用辅料有限公司 | 一种采用管道反应器制备磺丁基醚-β-环糊精的方法 |
| WO2025229196A1 (en) | 2024-05-03 | 2025-11-06 | Aalborg Universitet | Primary side modified sulfoalkyl ether- and hydroxypropyl-cyclodextrins, synthesis and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| ATE323110T1 (de) * | 1997-07-01 | 2006-04-15 | Pfizer Prod Inc | Verfahren zur herstellung von einem cyclodextrin |
| US6337380B1 (en) * | 1998-12-01 | 2002-01-08 | Fuji Photo Film Co., Ltd. | Polymer having sulfonic acid group and silver halide photographic photosensitive material using the polymer |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| CN100503647C (zh) | 2005-11-02 | 2009-06-24 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
| RU2470636C2 (ru) * | 2007-04-27 | 2012-12-27 | Сайдекс Фамэсьютиклз, Инк. | Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты) |
| US7635773B2 (en) * | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US9751957B2 (en) | 2012-02-15 | 2017-09-05 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| BR112012028726B1 (pt) | 2012-05-08 | 2021-07-13 | Onyx Therapeutics, Inc. | Método para preparar uma composição farmacêutica com baixo teor de cloreto |
-
2013
- 2013-07-17 GB GBGB1312737.8A patent/GB201312737D0/en not_active Ceased
-
2014
- 2014-07-16 WO PCT/GB2014/052173 patent/WO2015008066A1/en not_active Ceased
- 2014-07-16 PT PT147423222T patent/PT3022231T/pt unknown
- 2014-07-16 AP AP2016008975A patent/AP2016008975A0/xx unknown
- 2014-07-16 EP EP14742322.2A patent/EP3022231B1/en active Active
- 2014-07-16 US US14/333,417 patent/US11117978B2/en active Active
- 2014-07-16 CN CN201480040709.2A patent/CN105431458A/zh active Pending
- 2014-07-16 GB GB2015609.7A patent/GB2586104B/en active Active
- 2014-07-16 KR KR1020167003973A patent/KR20160031019A/ko not_active Withdrawn
- 2014-07-16 JP JP2016526700A patent/JP2016525600A/ja active Pending
- 2014-07-16 GB GB1412644.5A patent/GB2519832B/en active Active
- 2014-07-16 MX MX2016000553A patent/MX2016000553A/es unknown
- 2014-07-16 HU HUE14742322A patent/HUE038911T2/hu unknown
- 2014-07-16 AU AU2014291800A patent/AU2014291800A1/en not_active Abandoned
- 2014-07-16 CA CA2919501A patent/CA2919501A1/en not_active Abandoned
-
2015
- 2015-09-30 US US14/871,649 patent/US10239961B2/en active Active
-
2016
- 2016-01-14 CL CL2016000082A patent/CL2016000082A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3022231B1 (en) | 2018-04-18 |
| US11117978B2 (en) | 2021-09-14 |
| KR20160031019A (ko) | 2016-03-21 |
| GB2586104B (en) | 2021-03-31 |
| MX2016000553A (es) | 2016-08-01 |
| GB201412644D0 (en) | 2014-08-27 |
| GB2519832A (en) | 2015-05-06 |
| GB201312737D0 (en) | 2013-08-28 |
| WO2015008066A1 (en) | 2015-01-22 |
| HUE038911T2 (hu) | 2018-12-28 |
| CN105431458A (zh) | 2016-03-23 |
| EP3022231A1 (en) | 2016-05-25 |
| PT3022231T (pt) | 2018-06-11 |
| AP2016008975A0 (en) | 2016-01-31 |
| GB202015609D0 (en) | 2020-11-18 |
| AU2014291800A1 (en) | 2016-02-11 |
| CA2919501A1 (en) | 2015-01-22 |
| GB2586104A (en) | 2021-02-03 |
| US20160024229A1 (en) | 2016-01-28 |
| CL2016000082A1 (es) | 2016-09-23 |
| US10239961B2 (en) | 2019-03-26 |
| US20150025023A1 (en) | 2015-01-22 |
| GB2519832B (en) | 2021-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525600A (ja) | シクロデキストリン | |
| Sarabia-Vallejo et al. | Cyclodextrin inclusion complexes for improved drug bioavailability and activity: synthetic and analytical aspects | |
| JP6508944B2 (ja) | シクロデキストリン誘導体のための製造方法 | |
| Boye et al. | From 1D rods to 3D networks: A biohybrid topological diversity investigated by asymmetrical flow field-flow fractionation | |
| Spiridon et al. | Cyclodextrins as multifunctional platforms in drug delivery and beyond: structural features, functional applications, and future trends | |
| Kono et al. | Elucidation of substituent distribution states for carboxymethyl chitosan by detailed NMR analysis | |
| CN108778338A (zh) | 活性药物成分的连续络合 | |
| KR102113707B1 (ko) | 글리코겐-기반 수용성 향상제 | |
| Nan et al. | An economic, accessible and stable sulphated cyclodextrin polymer as selector for efficiently separating chiral drugs in HPLC | |
| Tongiani et al. | Sulfoalkyl ether-alkyl ether cyclodextrin derivatives, their synthesis, NMR characterization, and binding of 6α-methylprednisolone | |
| CN107574198B (zh) | 一种采用醇沉分级制备螺旋糊精包结络合载体的方法 | |
| Furuishi et al. | Effect of sulfobutyl ether-β-cyclodextrin and propylene glycol alginate on the solubility of clozapine | |
| Pham et al. | New method for preparing purity β-D-glucans (beta-Glucan) from baker’s yeast (Saccharomyces cerevisiae) | |
| JP2003342302A (ja) | 最低有効塩基性度のレベルにおけるシクロデキストリンの選択的アルキル化 | |
| Yudiarto et al. | Separation of structural isomers using soluble β-cyclodextrin polymer by ultrafiltration | |
| CN116655831B (zh) | 一种磺丁基-β-环糊精的制备方法 | |
| Savage et al. | Continuous tank reactor synthesis of highly substituted sulphobutylether β-cyclodextrins | |
| CN101224298B (zh) | 一种丙泊酚组合物 | |
| US20140148591A1 (en) | Method of removing alkylene halogenohydrin from cellulose ether | |
| CN1709918A (zh) | 不定位甲基化β-环糊精的合成工艺 | |
| US8865887B2 (en) | Method for synthesizing calixarene and/or cyclodextrin copolymers, terpolymers and tetrapolymers, and uses thereof | |
| CN101590029A (zh) | 一种丙泊酚组合物 | |
| Zielińska-Pisklak et al. | Complexes of Fat-Soluble Vitamins with Cyclodextrins | |
| FR2954771A1 (fr) | Nouveau procede de synthese de copolymeres, terpolymeres et tetrapolymeres de cyclodextrines et leurs utilisations | |
| JP2019196340A (ja) | セサミノールとシクロデキストリンとの包接複合体及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160712 |